# Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, and Malignant Pleural Mesotheliomas

> **NCT01143545** · PHASE1 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 10 (actual)

## Conditions studied

- Lung Cancer
- Esophageal Cancer
- Malignant Pleural Mesothelioma
- Sarcoma
- Thymic Carcinoma

## Interventions

- **BIOLOGICAL:** Allogeneic Tumor Cell Vaccine (K562)
- **DRUG:** Celecoxib
- **DRUG:** cyclophosphamide

## Key facts

- **NCT ID:** NCT01143545
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-12-07
- **Primary completion:** 2015-02-09
- **Final completion:** 2020-02-26
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** Closed accrual due to unpromising results and the opening of study 14C0053 targeting the same population.
- **Last updated:** 2020-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01143545

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01143545, "Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, and Malignant Pleural Mesotheliomas". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01143545. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*